Scolaris Content Display Scolaris Content Display

Study flow diagram
Figuras y tablas -
Figure 1

Study flow diagram

Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included trials.
Figuras y tablas -
Figure 2

Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included trials.

Risk of bias summary: review authors' judgements about each risk of bias item for each included trial.
Figuras y tablas -
Figure 3

Risk of bias summary: review authors' judgements about each risk of bias item for each included trial.

Trial Sequential Analysis comparing gemcitabine plus S‐1 versus S‐1 alone on the outcome 'all‐cause mortality'. The diversity‐adjusted required information size (DARIS) of n = 2655 trial participants was calculated based upon a proportion of mortality of 70% of the trial participants in the S‐1 group, a relative risk reduction of 20% in the gemcitabine + S‐1 group, an alpha (type I error) of 2.5%, a beta (type II error) of 10%, and a diversity of 78%. The blue curve presents the cumulative meta‐analysis Z‐score, and the inward‐sloping dotted red curves present the adjusted threshold for statistical significance according to the two‐sided trial sequential monitoring boundaries. The Trial Sequential Analysis‐adjusted CI was 0.27 to 1.40.
Figuras y tablas -
Figure 4

Trial Sequential Analysis comparing gemcitabine plus S‐1 versus S‐1 alone on the outcome 'all‐cause mortality'. The diversity‐adjusted required information size (DARIS) of n = 2655 trial participants was calculated based upon a proportion of mortality of 70% of the trial participants in the S‐1 group, a relative risk reduction of 20% in the gemcitabine + S‐1 group, an alpha (type I error) of 2.5%, a beta (type II error) of 10%, and a diversity of 78%. The blue curve presents the cumulative meta‐analysis Z‐score, and the inward‐sloping dotted red curves present the adjusted threshold for statistical significance according to the two‐sided trial sequential monitoring boundaries. The Trial Sequential Analysis‐adjusted CI was 0.27 to 1.40.

Comparison 1 Gemcitabine plus vandetanib versus vandetanib alone, Outcome 1 Serious adverse events.
Figuras y tablas -
Analysis 1.1

Comparison 1 Gemcitabine plus vandetanib versus vandetanib alone, Outcome 1 Serious adverse events.

Comparison 1 Gemcitabine plus vandetanib versus vandetanib alone, Outcome 2 Overall response rate.
Figuras y tablas -
Analysis 1.2

Comparison 1 Gemcitabine plus vandetanib versus vandetanib alone, Outcome 2 Overall response rate.

Comparison 1 Gemcitabine plus vandetanib versus vandetanib alone, Outcome 3 Grade 1 ‐ 4 anaemia.
Figuras y tablas -
Analysis 1.3

Comparison 1 Gemcitabine plus vandetanib versus vandetanib alone, Outcome 3 Grade 1 ‐ 4 anaemia.

Comparison 1 Gemcitabine plus vandetanib versus vandetanib alone, Outcome 4 Grade 3 ‐ 4 anaemia.
Figuras y tablas -
Analysis 1.4

Comparison 1 Gemcitabine plus vandetanib versus vandetanib alone, Outcome 4 Grade 3 ‐ 4 anaemia.

Comparison 1 Gemcitabine plus vandetanib versus vandetanib alone, Outcome 5 Grade 1 ‐ 4 neutropenia.
Figuras y tablas -
Analysis 1.5

Comparison 1 Gemcitabine plus vandetanib versus vandetanib alone, Outcome 5 Grade 1 ‐ 4 neutropenia.

Comparison 1 Gemcitabine plus vandetanib versus vandetanib alone, Outcome 6 Grade 3 ‐ 4 neutropenia.
Figuras y tablas -
Analysis 1.6

Comparison 1 Gemcitabine plus vandetanib versus vandetanib alone, Outcome 6 Grade 3 ‐ 4 neutropenia.

Comparison 2 Gemcitabine versus vandetanib, Outcome 1 Serious adverse events.
Figuras y tablas -
Analysis 2.1

Comparison 2 Gemcitabine versus vandetanib, Outcome 1 Serious adverse events.

Comparison 2 Gemcitabine versus vandetanib, Outcome 2 Overall response rate.
Figuras y tablas -
Analysis 2.2

Comparison 2 Gemcitabine versus vandetanib, Outcome 2 Overall response rate.

Comparison 2 Gemcitabine versus vandetanib, Outcome 3 Grade 1 ‐ 4 anaemia.
Figuras y tablas -
Analysis 2.3

Comparison 2 Gemcitabine versus vandetanib, Outcome 3 Grade 1 ‐ 4 anaemia.

Comparison 2 Gemcitabine versus vandetanib, Outcome 4 Grade 3 ‐ 4 anaemia.
Figuras y tablas -
Analysis 2.4

Comparison 2 Gemcitabine versus vandetanib, Outcome 4 Grade 3 ‐ 4 anaemia.

Comparison 2 Gemcitabine versus vandetanib, Outcome 5 Grade 1 ‐ 4 neutropenia.
Figuras y tablas -
Analysis 2.5

Comparison 2 Gemcitabine versus vandetanib, Outcome 5 Grade 1 ‐ 4 neutropenia.

Comparison 2 Gemcitabine versus vandetanib, Outcome 6 Grade 3 ‐ 4 neutropenia.
Figuras y tablas -
Analysis 2.6

Comparison 2 Gemcitabine versus vandetanib, Outcome 6 Grade 3 ‐ 4 neutropenia.

Comparison 3 Gemcitabine plus cisplatin versus S‐1 plus cisplatin, Outcome 1 All‐cause mortality at one year.
Figuras y tablas -
Analysis 3.1

Comparison 3 Gemcitabine plus cisplatin versus S‐1 plus cisplatin, Outcome 1 All‐cause mortality at one year.

Comparison 3 Gemcitabine plus cisplatin versus S‐1 plus cisplatin, Outcome 2 Overall response rate.
Figuras y tablas -
Analysis 3.2

Comparison 3 Gemcitabine plus cisplatin versus S‐1 plus cisplatin, Outcome 2 Overall response rate.

Comparison 3 Gemcitabine plus cisplatin versus S‐1 plus cisplatin, Outcome 3 Grade 1 ‐ 4 anaemia.
Figuras y tablas -
Analysis 3.3

Comparison 3 Gemcitabine plus cisplatin versus S‐1 plus cisplatin, Outcome 3 Grade 1 ‐ 4 anaemia.

Comparison 3 Gemcitabine plus cisplatin versus S‐1 plus cisplatin, Outcome 4 Grade 3 ‐ 4 anaemia.
Figuras y tablas -
Analysis 3.4

Comparison 3 Gemcitabine plus cisplatin versus S‐1 plus cisplatin, Outcome 4 Grade 3 ‐ 4 anaemia.

Comparison 3 Gemcitabine plus cisplatin versus S‐1 plus cisplatin, Outcome 5 Grade 1 ‐ 4 thrombocytopenia.
Figuras y tablas -
Analysis 3.5

Comparison 3 Gemcitabine plus cisplatin versus S‐1 plus cisplatin, Outcome 5 Grade 1 ‐ 4 thrombocytopenia.

Comparison 3 Gemcitabine plus cisplatin versus S‐1 plus cisplatin, Outcome 6 Grade 3 ‐ 4 thrombocytopenia.
Figuras y tablas -
Analysis 3.6

Comparison 3 Gemcitabine plus cisplatin versus S‐1 plus cisplatin, Outcome 6 Grade 3 ‐ 4 thrombocytopenia.

Comparison 3 Gemcitabine plus cisplatin versus S‐1 plus cisplatin, Outcome 7 Grade 1 ‐ 4 neutropenia.
Figuras y tablas -
Analysis 3.7

Comparison 3 Gemcitabine plus cisplatin versus S‐1 plus cisplatin, Outcome 7 Grade 1 ‐ 4 neutropenia.

Comparison 3 Gemcitabine plus cisplatin versus S‐1 plus cisplatin, Outcome 8 Grade 3 ‐ 4 neutropenia.
Figuras y tablas -
Analysis 3.8

Comparison 3 Gemcitabine plus cisplatin versus S‐1 plus cisplatin, Outcome 8 Grade 3 ‐ 4 neutropenia.

Comparison 3 Gemcitabine plus cisplatin versus S‐1 plus cisplatin, Outcome 9 Febrile neutropenia.
Figuras y tablas -
Analysis 3.9

Comparison 3 Gemcitabine plus cisplatin versus S‐1 plus cisplatin, Outcome 9 Febrile neutropenia.

Comparison 4 Gemcitabine plus S‐1 versus S‐1, Outcome 1 All‐cause mortality at one year.
Figuras y tablas -
Analysis 4.1

Comparison 4 Gemcitabine plus S‐1 versus S‐1, Outcome 1 All‐cause mortality at one year.

Comparison 4 Gemcitabine plus S‐1 versus S‐1, Outcome 2 Serious adverse events.
Figuras y tablas -
Analysis 4.2

Comparison 4 Gemcitabine plus S‐1 versus S‐1, Outcome 2 Serious adverse events.

Comparison 4 Gemcitabine plus S‐1 versus S‐1, Outcome 3 Overall response rate.
Figuras y tablas -
Analysis 4.3

Comparison 4 Gemcitabine plus S‐1 versus S‐1, Outcome 3 Overall response rate.

Comparison 4 Gemcitabine plus S‐1 versus S‐1, Outcome 4 Grade 1 ‐ 4 anaemia.
Figuras y tablas -
Analysis 4.4

Comparison 4 Gemcitabine plus S‐1 versus S‐1, Outcome 4 Grade 1 ‐ 4 anaemia.

Comparison 4 Gemcitabine plus S‐1 versus S‐1, Outcome 5 Grade 3 ‐ 4 anaemia.
Figuras y tablas -
Analysis 4.5

Comparison 4 Gemcitabine plus S‐1 versus S‐1, Outcome 5 Grade 3 ‐ 4 anaemia.

Comparison 4 Gemcitabine plus S‐1 versus S‐1, Outcome 6 Grade 1 ‐ 4 thrombocytopenia.
Figuras y tablas -
Analysis 4.6

Comparison 4 Gemcitabine plus S‐1 versus S‐1, Outcome 6 Grade 1 ‐ 4 thrombocytopenia.

Comparison 4 Gemcitabine plus S‐1 versus S‐1, Outcome 7 Grade 3 ‐ 4 thrombocytopenia.
Figuras y tablas -
Analysis 4.7

Comparison 4 Gemcitabine plus S‐1 versus S‐1, Outcome 7 Grade 3 ‐ 4 thrombocytopenia.

Comparison 4 Gemcitabine plus S‐1 versus S‐1, Outcome 8 Grade 1 ‐ 4 neutropenia.
Figuras y tablas -
Analysis 4.8

Comparison 4 Gemcitabine plus S‐1 versus S‐1, Outcome 8 Grade 1 ‐ 4 neutropenia.

Comparison 4 Gemcitabine plus S‐1 versus S‐1, Outcome 9 Grade 3 ‐ 4 neutropenia.
Figuras y tablas -
Analysis 4.9

Comparison 4 Gemcitabine plus S‐1 versus S‐1, Outcome 9 Grade 3 ‐ 4 neutropenia.

Comparison 4 Gemcitabine plus S‐1 versus S‐1, Outcome 10 Febrile neutropenia.
Figuras y tablas -
Analysis 4.10

Comparison 4 Gemcitabine plus S‐1 versus S‐1, Outcome 10 Febrile neutropenia.

Comparison 5 Gemcitabine plus oxaliplatin versus best supportive care, Outcome 1 All‐cause mortality at one year.
Figuras y tablas -
Analysis 5.1

Comparison 5 Gemcitabine plus oxaliplatin versus best supportive care, Outcome 1 All‐cause mortality at one year.

Comparison 5 Gemcitabine plus oxaliplatin versus best supportive care, Outcome 2 Overall response rate.
Figuras y tablas -
Analysis 5.2

Comparison 5 Gemcitabine plus oxaliplatin versus best supportive care, Outcome 2 Overall response rate.

Comparison 6 Gemcitabine plus oxaliplatin versus fluorouracil plus folinic acid, Outcome 1 All‐cause mortality at one year.
Figuras y tablas -
Analysis 6.1

Comparison 6 Gemcitabine plus oxaliplatin versus fluorouracil plus folinic acid, Outcome 1 All‐cause mortality at one year.

Comparison 6 Gemcitabine plus oxaliplatin versus fluorouracil plus folinic acid, Outcome 2 Overall response rate.
Figuras y tablas -
Analysis 6.2

Comparison 6 Gemcitabine plus oxaliplatin versus fluorouracil plus folinic acid, Outcome 2 Overall response rate.

Comparison 7 Gemcitabine plus oxaliplatin versus 5‐fluorouracil plus cisplatin plus radiotherapy, Outcome 1 All‐cause mortality at one year.
Figuras y tablas -
Analysis 7.1

Comparison 7 Gemcitabine plus oxaliplatin versus 5‐fluorouracil plus cisplatin plus radiotherapy, Outcome 1 All‐cause mortality at one year.

Comparison 7 Gemcitabine plus oxaliplatin versus 5‐fluorouracil plus cisplatin plus radiotherapy, Outcome 2 Serious adverse events.
Figuras y tablas -
Analysis 7.2

Comparison 7 Gemcitabine plus oxaliplatin versus 5‐fluorouracil plus cisplatin plus radiotherapy, Outcome 2 Serious adverse events.

Comparison 7 Gemcitabine plus oxaliplatin versus 5‐fluorouracil plus cisplatin plus radiotherapy, Outcome 3 Grade 3 ‐ 4 neutropenia.
Figuras y tablas -
Analysis 7.3

Comparison 7 Gemcitabine plus oxaliplatin versus 5‐fluorouracil plus cisplatin plus radiotherapy, Outcome 3 Grade 3 ‐ 4 neutropenia.

Comparison 8 Gemcitabine plus mitomycin C versus capecitabine plus mitomycin C, Outcome 1 All‐cause mortality at one year.
Figuras y tablas -
Analysis 8.1

Comparison 8 Gemcitabine plus mitomycin C versus capecitabine plus mitomycin C, Outcome 1 All‐cause mortality at one year.

Comparison 8 Gemcitabine plus mitomycin C versus capecitabine plus mitomycin C, Outcome 2 Overall response rate.
Figuras y tablas -
Analysis 8.2

Comparison 8 Gemcitabine plus mitomycin C versus capecitabine plus mitomycin C, Outcome 2 Overall response rate.

Comparison 8 Gemcitabine plus mitomycin C versus capecitabine plus mitomycin C, Outcome 3 Grade 1 ‐ 4 thrombocytopenia.
Figuras y tablas -
Analysis 8.3

Comparison 8 Gemcitabine plus mitomycin C versus capecitabine plus mitomycin C, Outcome 3 Grade 1 ‐ 4 thrombocytopenia.

Comparison 8 Gemcitabine plus mitomycin C versus capecitabine plus mitomycin C, Outcome 4 Grade 3 ‐ 4 thrombocytopenia.
Figuras y tablas -
Analysis 8.4

Comparison 8 Gemcitabine plus mitomycin C versus capecitabine plus mitomycin C, Outcome 4 Grade 3 ‐ 4 thrombocytopenia.

Summary of findings for the main comparison. Gemcitabine plus vandetanib compared with vandetanib for advanced biliary tract carcinomas

Gemcitabine plus vandetanib compared with vandetanib for advanced biliary tract carcinomas

Patient or population: people with advanced biliary tract carcinomas
Setting: specialist hospitals
Intervention: gemcitabine plus vandetanib
Comparison: vandetanib

Outcomes

Anticipated absolute effects* (95% CI)

Relative effect
(95% CI)

№ of participants
(studies)

Certainty of the evidence
(GRADE)

Comments

Risk with vandetanib

Risk with gemcitabine plus vandetanib

All‐cause mortality at 1 year

Not reported

Serious adverse events

Study population

RR 0.95
(0.52 to 1.74)

117
(1 RCT)

⊕⊝⊝⊝
VERY LOW1

271 per 1000

258 per 1000
(141 to 472)

Health‐related quality of life

Not reported

Overall response rate

Study population

RR 5.40
(1.25 to 23.29)

113
(1 RCT)

⊕⊝⊝⊝
VERY LOW1

36 per 1000

193 per 1000
(45 to 832)

Time to progression of the tumour

Not reported

Grade 1 ‐ 4 anaemia

Study population

RR 7.12
(0.90 to 56.08)

117
(1 RCT)

⊕⊝⊝⊝
VERY LOW1

17 per 1000

121 per 1000
(15 to 951)

*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).

CI: Confidence interval; RR: Risk ratio; RCT: randomised clinical trial

GRADE Working Group grades of evidence
High certainty: We are very confident that the true effect lies close to that of the estimate of the effect.
Moderate certainty: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.
Low certainty: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect.
Very low certainty: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect.

1Downgraded three levels (‐3) because of i) within‐study risk of bias due to high risk of bias; ii) publication bias could not be assessed; iii) imprecision due to small number of trials (one trial)

Figuras y tablas -
Summary of findings for the main comparison. Gemcitabine plus vandetanib compared with vandetanib for advanced biliary tract carcinomas
Summary of findings 2. Gemcitabine versus vandetanib for advanced biliary tract carcinomas

Gemcitabine compared with vandetanib for advanced biliary tract carcinomas

Patient or population: people with advanced biliary tract carcinomas
Setting: specialist hospitals

Intervention: gemcitabine

Comparison: vandetanib

Outcomes

Illustrative comparative risks* (95% CI)

Relative effect
(95% CI)

No of Participants
(studies)

Quality of the evidence
(GRADE)

Comments

Assumed risk

Corresponding risk

Risk with vandetanib

Risk with gemcitabine

All‐cause mortality at 1 year

Not reported

Serious adverse events

271 per 1000

214 per 1000
(111 to 412)

RR 0.79 (0.41 to 1.52)

115

(1 RCT)

⊕⊝⊝⊝
VERY LOW1

Helath‐related quality of life

Not reported

Overall response rate

36 per 1000

135 per 1000
(29 to 619)

RR 3.77 (0.82 to 17.33)

108

(1 RCT)

⊕⊝⊝⊝
VERY LOW1

Time to progression of the tumour

Not reported

Grade 1 ‐ 4 anaemia

17 per 1000

125 per 1000

(16 to 984)

RR 7.38 (0.94 to 58.05)

115

(1 RCT)

⊕⊝⊝⊝
VERY LOW1

*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; RR: Risk ratio; RCT: randomised clinical trial

GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.

1Downgraded three levels (‐3) because of i) within‐study risk of bias due to high risk of bias; ii) publication bias could not be assessed; iii) imprecision due to small number of trials (one trial)

Figuras y tablas -
Summary of findings 2. Gemcitabine versus vandetanib for advanced biliary tract carcinomas
Summary of findings 3. Gemcitabine plus cisplatin compared with S‐1 plus cisplatin for advanced biliary tract carcinomas

Gemcitabine plus cisplatin compared with S‐1 plus cisplatin for advanced biliary tract carcinomas

Patient or population: people with advanced biliary tract carcinomas
Setting: specialist hospitals
Intervention: gemcitabine plus cisplatin
Comparison: S‐1 plus cisplatin

Outcomes

Anticipated absolute effects* (95% CI)

Relative effect
(95% CI)

№ of participants
(studies)

Certainty of the evidence
(GRADE)

Comments

Risk with S‐1 plus cisplatin

Risk with gemcitabine plus cisplatin

All‐cause mortality at 1 year

Study population

RR 0.76
(0.58 to 0.98)

96
(1 RCT)

⊕⊝⊝⊝
VERY LOW1

809 per 1000

614 per 1000
(469 to 792)

Serious adverse events

Not reported

Health‐related quality of life

Not reported

Overall response rate

Study population

RR 0.82
(0.37 to 1.82)

88
(1 RCT)

⊕⊝⊝⊝
VERY LOW1

238 per 1000

195 per 1000
(88 to 433)

Time to progression of the tumour

Not reported

Grade 1 ‐ 4 anaemia

Study population

RR 11.27
(4.41 to 28.83)

96
(1 RCT)

⊕⊝⊝⊝
VERY LOW1

85 per 1000

959 per 1000
(375 to 1000)

*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).

CI: Confidence interval; RR: Risk ratio; RCT: randomised clinical trial

GRADE Working Group grades of evidence
High certainty: We are very confident that the true effect lies close to that of the estimate of the effect.
Moderate certainty: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.
Low certainty: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect.
Very low certainty: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect.

1Downgraded three levels (‐3) because of i) within‐study risk of bias due to high risk of bias; ii) publication bias could not be assessed; iii) imprecision due to small number of trials (one trial)

Figuras y tablas -
Summary of findings 3. Gemcitabine plus cisplatin compared with S‐1 plus cisplatin for advanced biliary tract carcinomas
Summary of findings 4. Gemcitabine plus S‐1 compared with S‐1 for advanced biliary tract carcinomas

Gemcitabine plus S‐1 compared with S‐1 for advanced biliary tract carcinomas

Patient or population: people with advanced biliary tract carcinomas
Setting: specialist hospitals
Intervention: gemcitabine plus S‐1
Comparison: S‐1

Outcomes

Anticipated absolute effects* (95% CI)

Relative effect
(95% CI)

№ of participants
(studies)

Certainty of the evidence
(GRADE)

Comments

Risk with S‐1

Risk with gemcitabine plus S‐1

All‐cause mortality at 1 year

Study population

RR 0.61
(0.33 to 1.13)

151
(2 RCTs)

⊕⊝⊝⊝
VERY LOW1

707 per 1000

431 per 1000
(233 to 799)

Serious adverse events

Study population

RR 1.05
(0.15 to 7.10)

90
(1 RCT)

⊕⊝⊝⊝
VERY LOW1

43 per 1000

46 per 1000
(7 to 309)

Health‐related quality of life

Not reported

Overall response rate

Study population

RR 2.46
(1.27 to 4.75)

140
(2 RCTs)

⊕⊝⊝⊝
VERY LOW1

Not supported by Trial Sequential Analysis

141 per 1000

346 per 1000
(179 to 669)

Time to progression of the tumour

Not reported

Grade 1 ‐ 4 anaemia

Study population

RR 1.26
(1.00 to 1.59)

151
(2 RCTs)

⊕⊝⊝⊝
VERY LOW1

480 per 1000

605 per 1000
(480 to 763)

*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).

CI: Confidence interval; RR: Risk ratio; RCT: randomised clinical trial

GRADE Working Group grades of evidence
High certainty: We are very confident that the true effect lies close to that of the estimate of the effect.
Moderate certainty: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.
Low certainty: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect.
Very low certainty: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect.

1Downgraded three levels (‐3) because of i) within‐study risk of bias due to high risk of bias; ii) publication bias could not be assessed; iii) imprecision due to small number of trials (two trials)

Figuras y tablas -
Summary of findings 4. Gemcitabine plus S‐1 compared with S‐1 for advanced biliary tract carcinomas
Summary of findings 5. Gemcitabine plus oxaliplatin compared with best supportive care for advanced biliary tract carcinomas

Gemcitabine plus oxaliplatin compared with best supportive care for advanced biliary tract carcinomas

Patient or population: people with advanced biliary tract carcinomas
Setting: specialist hospitals
Intervention: gemcitabine plus oxaliplatin
Comparison: best supportive care

Outcomes

Anticipated absolute effects* (95% CI)

Relative effect
(95% CI)

№ of participants
(studies)

Certainty of the evidence
(GRADE)

Comments

Risk with best supportive care

Risk with gemcitabine plus oxaliplatin

All‐cause mortality at 1 year

Study population

RR 0.78
(0.53 to 1.15)

40
(1 RCT)

⊕⊝⊝⊝
VERY LOW1

889 per 1000

693 per 1000
(471 to 1000)

Serious adverse events

Not reported

Health‐related quality of life

Not reported

Overall response rate

Study population

RR 34.00
(2.11 to 547.54)

40
(1 RCT)

⊕⊝⊝⊝
VERY LOW1

0 per 1000

0 per 1000
(0 to 0)

Time to progression of the tumour

Not reported

*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).

CI: Confidence interval; RR: Risk ratio; RCT: randomised clinical trial

GRADE Working Group grades of evidence
High certainty: We are very confident that the true effect lies close to that of the estimate of the effect.
Moderate certainty: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.
Low certainty: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect.
Very low certainty: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect.

1Downgraded three levels (‐3) because of i) within‐study risk of bias due to high risk of bias; ii) publication bias could not be assessed; iii) imprecision due to small number of trials (one trial)

Figuras y tablas -
Summary of findings 5. Gemcitabine plus oxaliplatin compared with best supportive care for advanced biliary tract carcinomas
Summary of findings 6. Gemcitabine plus oxaliplatin compared with 5‐fluorouracil plus folinic acid for advanced biliary tract carcinomas

Gemcitabine plus oxaliplatin compared with fluorouracil plus folinic acid for advanced biliary tract carcinomas

Patient or population: people with advanced biliary tract carcinomas
Setting: specialist hospitals
Intervention: gemcitabine plus oxaliplatin
Comparison: fluorouracil plus folinic acid

Outcomes

Anticipated absolute effects* (95% CI)

Relative effect
(95% CI)

№ of participants
(studies)

Certainty of the evidence
(GRADE)

Comments

Risk with fluorouracil plus folinic acid

Risk with gemcitabine plus oxaliplatin

All‐cause mortality at 1 year

Study population

RR 0.81
(0.55 to 1.20)

41
(1 RCT)

⊕⊝⊝⊝
VERY LOW1

857 per 1000

694 per 1000
(471 to 1000)

Serious adverse events

Not reported

Helath‐related quality of life

Not reported

Overall response rate

Study population

RR 2.15
(0.64 to 7.29)

41
(1 RCT)

⊕⊝⊝⊝
VERY LOW1

143 per 1000

307 per 1000
(91 to 1000)

Time to progression of the tumour

Not reported

*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).

CI: Confidence interval; RR: Risk ratio; RCT: randomised clinical trial

GRADE Working Group grades of evidence
High certainty: We are very confident that the true effect lies close to that of the estimate of the effect.
Moderate certainty: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.
Low certainty: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect.
Very low certainty: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect.

1Downgraded three levels (‐3) because of i) within‐study risk of bias due to high risk of bias; ii) publication bias could not be assessed; iii) imprecision due to small number of trials (one trial)

Figuras y tablas -
Summary of findings 6. Gemcitabine plus oxaliplatin compared with 5‐fluorouracil plus folinic acid for advanced biliary tract carcinomas
Summary of findings 7. Gemcitabine plus oxaliplatin compared with 5‐fluorouracil plus cisplatin plus radiotherapy for advanced biliary tract carcinomas

Gemcitabine plus oxaliplatin compared with fluorouracil plus cisplatin plus radiotherapy for advanced biliary tract carcinomas

Patient or population: people with advanced biliary tract carcinomas
Setting: specialist hospitals
Intervention: gemcitabine plus oxaliplatin
Comparison: fluorouracil plus cisplatin plus radiotherapy

Outcomes

Anticipated absolute effects* (95% CI)

Relative effect
(95% CI)

№ of participants
(studies)

Certainty of the evidence
(GRADE)

Comments

Risk with fluorouracil and cisplatin plus radiotherapy

Risk with gemcitabine plus oxaliplatin

All‐cause mortality at 1 year

Study population

RR 0.56
(0.21 to 1.52)

34
(1 RCT)

⊕⊝⊝⊝
VERY LOW1

444 per 1000

249 per 1000
(93 to 676)

Serious adverse events

Study population

RR 1.50
(0.66 to 3.39)

34
(1 RCT)

⊕⊝⊝⊝
VERY LOW1

333 per 1000

500 per 1000
(220 to 1000)

Health‐related quality of life

Not reported

Overall response rate

Not reported

Time to progression of the tumour

Not reported

*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).

CI: Confidence interval; RR: Risk ratio; RCT: randomised clinical trial

GRADE Working Group grades of evidence
High certainty: We are very confident that the true effect lies close to that of the estimate of the effect.
Moderate certainty: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.
Low certainty: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect.
Very low certainty: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect.

1Downgraded three levels (‐3) because of i) within‐study risk of bias due to high risk of bias; ii) publication bias could not be assessed; iii) imprecision due to small number of trials (one trial)

Figuras y tablas -
Summary of findings 7. Gemcitabine plus oxaliplatin compared with 5‐fluorouracil plus cisplatin plus radiotherapy for advanced biliary tract carcinomas
Summary of findings 8. Gemcitabine plus mitomycin C compared with capecitabine plus mitomycin C for advanced biliary tract carcinomas

Gemcitabine plus mitomycin C compared with mitomycin C plus capecitabine for advanced biliary tract carcinomas

Patient or population: people with advanced biliary tract carcinomas
Setting: specialist hospitals
Intervention: gemcitabine plus mitomycin C
Comparison: capecitabine plus mitomycin C

Outcomes

Anticipated absolute effects* (95% CI)

Relative effect
(95% CI)

№ of participants
(studies)

Certainty of the evidence
(GRADE)

Comments

Risk with capecitabine plus mitomycin C

Risk with gemcitabine plus mitomycin C

All‐cause mortality at 1 year

Study population

RR 1.14
(0.89 to 1.48)

51
(1 RCT)

⊕⊝⊝⊝
VERY LOW1

769 per 1000

877 per 1000
(685 to 1000)

Serious adverse events

Not reported

Health‐related quality of life

Not reported

Overall response rate

Study population

RR 0.65
(0.25 to 1.72)

51
(1 RCT)

⊕⊝⊝⊝
VERY LOW1

308 per 1000

200 per 1000
(77 to 529)

Time to progression of the tumour

Not reported

Grade 1 ‐ 4 thrombocytopenia

Study population

RR 0.56
(0.29 to 1.06)

47
(1 RCT)

⊕⊝⊝⊝
VERY LOW1

625 per 1000

350 per 1000
(181 to 663)

*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).

CI: Confidence interval; RR: Risk ratio; RCT: randomised clinical trial

GRADE Working Group grades of evidence
High certainty: We are very confident that the true effect lies close to that of the estimate of the effect.
Moderate certainty: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.
Low certainty: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect.
Very low certainty: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect.

1Downgraded three levels (‐3) because of i) within‐study risk of bias due to high risk of bias; ii) publication bias could not be assessed; iii) imprecision due to small number of trials (one trial)

Figuras y tablas -
Summary of findings 8. Gemcitabine plus mitomycin C compared with capecitabine plus mitomycin C for advanced biliary tract carcinomas
Table 1. Explanations for Cochrane 'Summary of findings' tables

Examples from table

Explanation

Outcomes

The tables provide the findings for the most important outcomes for someone making a decision. These include potential benefits and harms, whether the included trials provide data for these outcomes or not. Additional findings may be reported elsewhere in the review.

Assumed control group risk

Assumed control group risks can be based either on the control group risks reported in the included trials or on epidemiological data from elsewhere. When only one control group risk is provided, it is normally the median control group risk across the trials that provided data for that outcome.

Risk is the probability of an outcome occurring. The control group risk is the risk of an outcome occurring in the comparison group (without the intervention).

Corresponding intervention group risk

Risk is the probability of an outcome occurring. The intervention group risk is the risk of an outcome occurring in the group receiving the intervention.

Relative effect

Relative effect or RR (risk ratio)

Relative effects are ratios. Here the relative effect is expressed as a risk ratio.

Risk is the probability of an outcome occurring. An RR is the ratio between the risk in the intervention group and the risk in the control group. If the risk in the control group is 10% (100 per 1000) and the risk in the intervention group is 1% (10 per 1000), the RR is 10/100 or 0.10.

If the RR is exactly 1.0, this means that there is no difference between the occurrence of the outcome in the intervention and the control group. It is unusual for the RR to be exactly 1.0, and understanding what it means if it is above or below this value depends on whether the outcome being counted is judged to be good or bad.

If the RR is greater than 1.0, the intervention increases the risk of the outcome. If it is a good outcome (e.g. the birth of a healthy baby), an RR > 1.0 indicates a desirable effect for the intervention, whereas if the outcome is bad (e.g. death), an RR > 1.0 would indicate an undesirable effect.

If the RR is less than 1.0, the intervention decreases the risk of the outcome. This indicates a desirable effect if it is a bad outcome (e.g. death) and an undesirable effect if it is a good outcome (e.g. birth of a healthy baby).

What is the difference between absolute and relative effects?

The effect of an intervention can be described by comparing the risk of the intervention group with the risk of the control group. Such a comparison can be made in different ways.

One way to compare two risks is to calculate the difference between the risks. This is the absolute effect.

Consider the risk for blindness in a person with diabetes over a five‐year period. If the risk for blindness is found to be 20 in 1000 (2%) in a group of people treated conventionally and 10 in 1000 (1%) in people treated with a new drug, the absolute effect is derived by subtracting the intervention group risk from the control group risk: 2%/1% = 1%. Expressed in this way, it can be said that the new drug reduces the five‐year risk for blindness by 1% (absolute effect is 10 fewer per 1000).

Another way to compare risks is to calculate the ratio of the two risks. Given the data above, the relative effect is derived by dividing the two risks, with the intervention risk being divided by the control risk: 1% ÷ 2% = ½ (0.50). Expressed in this way, as the 'relative effect', the five‐year risk for blindness with the new drug is 1/2 the risk with the conventional drug.

Here the table presents risks as x per 1000 (or 100, etc.) instead of %, as this tends to be easier to understand. Whenever possible, the table presents the relative effect as the RR.

Usually the absolute effect is different for groups that are at high and low risk, whereas the relative effect often is the same. Therefore, when it is relevant, we have reported indicative risks for groups at different levels of risk. Two or three indicative control group risks and the corresponding intervention group risks are presented when there are important differences across different populations.

Mean difference

The mean difference (MD) is the average difference between the intervention group and the control group across trials. Here a weighted MD is used, which means the results of some of the trials make a greater contribution to the average than others. Trials with more precise estimates for their results (narrower confidence intervals) are given more weight.

This way of measuring effect is used when combining or comparing data for continuous outcomes, such as weight, blood pressure, or pain measured on a scale. When different scales are used to measure the same outcome, e.g. different pain scales, a standardised mean difference (SMD) may be provided. This is a weighted mean difference standardised across trials giving the average difference in standard deviations for the measures of that outcome.

Confidence interval

A confidence interval (CI) is a range around an estimate that conveys how precise the estimate is; in this example the result is the estimate of the intervention group risk. The CI is a guide to how sure we can be about the quantity we are interested in (here the true absolute effect). The narrower the range between the two numbers, the more confident we can be about what the true value is; the wider the range, the less sure we can be. The width of the CI reflects the extent to which chance may be responsible for the observed estimate (with a wider interval reflecting more chance).

95% confidence interval

As explained above, the CI indicates the extent to which chance may be responsible for the observed numbers. In the simplest terms, a 95% CI means that we can be 95% confident that the true size of effect is between the lower and upper confidence limit (e.g. 0 and 3 in the blindness drugs example mentioned above). Conversely, there is a 5% chance that the true effect is outside of this range.

Not statistically significant

Statistically significant means that a result is unlikely to have occurred by chance. The usual threshold for this judgement is that the results, or more extreme results, would occur by chance with a probability of less than 0.05 if the null hypothesis (no effect) were true. When results are not statistically significant, as in this example, this is stated to alert users to the possibility that the results may have occurred by chance.

Number of participants (trials)

The table provides the total number of participants across trials and the number of trials that provided data for that outcome. This indicates how much evidence there is for the outcome.

Certainty of the evidence

The certainty of the evidence is a judgement about the extent to which we can be confident that the estimates of effect are correct. These judgements are made using the GRADE system, and are provided for each outcome. The judgements are based on the type of study design (randomised trials versus observational trials), the risk of bias, the consistency of the results across trials, and the precision of the overall estimate across trials.

For each outcome, the certainty of the evidence is rated as high, moderate, low, or very low using the following definitions:

  • High certainty: We are very confident that the true effect lies close to that of the estimate of the effect

  • Moderate certainty: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different

  • Low certainty: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect

  • Very low certainty: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect.

A ‐ indicates that the information is not relevant.

Figuras y tablas -
Table 1. Explanations for Cochrane 'Summary of findings' tables
Comparison 1. Gemcitabine plus vandetanib versus vandetanib alone

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Serious adverse events Show forest plot

1

Risk Ratio (M‐H, Random, 95% CI)

Totals not selected

2 Overall response rate Show forest plot

1

Risk Ratio (M‐H, Random, 95% CI)

Totals not selected

3 Grade 1 ‐ 4 anaemia Show forest plot

1

Risk Ratio (M‐H, Random, 95% CI)

Totals not selected

4 Grade 3 ‐ 4 anaemia Show forest plot

1

Risk Ratio (M‐H, Random, 95% CI)

Totals not selected

5 Grade 1 ‐ 4 neutropenia Show forest plot

1

Risk Ratio (M‐H, Random, 95% CI)

Totals not selected

6 Grade 3 ‐ 4 neutropenia Show forest plot

1

Risk Ratio (M‐H, Random, 95% CI)

Totals not selected

Figuras y tablas -
Comparison 1. Gemcitabine plus vandetanib versus vandetanib alone
Comparison 2. Gemcitabine versus vandetanib

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Serious adverse events Show forest plot

1

Risk Ratio (M‐H, Random, 95% CI)

Totals not selected

2 Overall response rate Show forest plot

1

Risk Ratio (M‐H, Random, 95% CI)

Totals not selected

3 Grade 1 ‐ 4 anaemia Show forest plot

1

Risk Ratio (M‐H, Random, 95% CI)

Totals not selected

4 Grade 3 ‐ 4 anaemia Show forest plot

1

Risk Ratio (M‐H, Random, 95% CI)

Totals not selected

5 Grade 1 ‐ 4 neutropenia Show forest plot

1

Risk Ratio (M‐H, Random, 95% CI)

Totals not selected

6 Grade 3 ‐ 4 neutropenia Show forest plot

1

Risk Ratio (M‐H, Random, 95% CI)

Totals not selected

Figuras y tablas -
Comparison 2. Gemcitabine versus vandetanib
Comparison 3. Gemcitabine plus cisplatin versus S‐1 plus cisplatin

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 All‐cause mortality at one year Show forest plot

1

Risk Ratio (M‐H, Random, 95% CI)

Totals not selected

2 Overall response rate Show forest plot

1

Risk Ratio (M‐H, Random, 95% CI)

Totals not selected

3 Grade 1 ‐ 4 anaemia Show forest plot

1

Risk Ratio (M‐H, Random, 95% CI)

Totals not selected

4 Grade 3 ‐ 4 anaemia Show forest plot

1

Risk Ratio (M‐H, Random, 95% CI)

Totals not selected

5 Grade 1 ‐ 4 thrombocytopenia Show forest plot

1

Risk Ratio (M‐H, Random, 95% CI)

Totals not selected

6 Grade 3 ‐ 4 thrombocytopenia Show forest plot

1

Risk Ratio (M‐H, Random, 95% CI)

Totals not selected

7 Grade 1 ‐ 4 neutropenia Show forest plot

1

Risk Ratio (M‐H, Random, 95% CI)

Totals not selected

8 Grade 3 ‐ 4 neutropenia Show forest plot

1

Risk Ratio (M‐H, Random, 95% CI)

Totals not selected

9 Febrile neutropenia Show forest plot

1

Risk Ratio (M‐H, Random, 95% CI)

Totals not selected

Figuras y tablas -
Comparison 3. Gemcitabine plus cisplatin versus S‐1 plus cisplatin
Comparison 4. Gemcitabine plus S‐1 versus S‐1

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 All‐cause mortality at one year Show forest plot

2

151

Risk Ratio (M‐H, Random, 95% CI)

0.61 [0.33, 1.13]

2 Serious adverse events Show forest plot

1

Risk Ratio (M‐H, Random, 95% CI)

Totals not selected

3 Overall response rate Show forest plot

2

140

Risk Ratio (M‐H, Random, 95% CI)

2.46 [1.27, 4.75]

4 Grade 1 ‐ 4 anaemia Show forest plot

2

151

Risk Ratio (M‐H, Random, 95% CI)

1.26 [1.00, 1.59]

5 Grade 3 ‐ 4 anaemia Show forest plot

1

Risk Ratio (M‐H, Random, 95% CI)

Totals not selected

6 Grade 1 ‐ 4 thrombocytopenia Show forest plot

2

151

Risk Ratio (M‐H, Random, 95% CI)

2.45 [1.39, 4.32]

7 Grade 3 ‐ 4 thrombocytopenia Show forest plot

1

Risk Ratio (M‐H, Random, 95% CI)

Totals not selected

8 Grade 1 ‐ 4 neutropenia Show forest plot

2

151

Risk Ratio (M‐H, Random, 95% CI)

3.30 [1.04, 10.50]

9 Grade 3 ‐ 4 neutropenia Show forest plot

1

Risk Ratio (M‐H, Random, 95% CI)

Totals not selected

10 Febrile neutropenia Show forest plot

2

151

Risk Ratio (M‐H, Random, 95% CI)

2.97 [0.32, 27.87]

Figuras y tablas -
Comparison 4. Gemcitabine plus S‐1 versus S‐1
Comparison 5. Gemcitabine plus oxaliplatin versus best supportive care

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 All‐cause mortality at one year Show forest plot

1

Risk Ratio (M‐H, Random, 95% CI)

Totals not selected

2 Overall response rate Show forest plot

1

Risk Ratio (M‐H, Random, 95% CI)

Totals not selected

Figuras y tablas -
Comparison 5. Gemcitabine plus oxaliplatin versus best supportive care
Comparison 6. Gemcitabine plus oxaliplatin versus fluorouracil plus folinic acid

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 All‐cause mortality at one year Show forest plot

1

Risk Ratio (M‐H, Random, 95% CI)

Totals not selected

2 Overall response rate Show forest plot

1

Risk Ratio (M‐H, Random, 95% CI)

Totals not selected

Figuras y tablas -
Comparison 6. Gemcitabine plus oxaliplatin versus fluorouracil plus folinic acid
Comparison 7. Gemcitabine plus oxaliplatin versus 5‐fluorouracil plus cisplatin plus radiotherapy

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 All‐cause mortality at one year Show forest plot

1

Risk Ratio (M‐H, Random, 95% CI)

Totals not selected

2 Serious adverse events Show forest plot

1

Risk Ratio (M‐H, Random, 95% CI)

Totals not selected

3 Grade 3 ‐ 4 neutropenia Show forest plot

1

Risk Ratio (M‐H, Random, 95% CI)

Totals not selected

Figuras y tablas -
Comparison 7. Gemcitabine plus oxaliplatin versus 5‐fluorouracil plus cisplatin plus radiotherapy
Comparison 8. Gemcitabine plus mitomycin C versus capecitabine plus mitomycin C

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 All‐cause mortality at one year Show forest plot

1

Risk Ratio (M‐H, Random, 95% CI)

Totals not selected

2 Overall response rate Show forest plot

1

Risk Ratio (M‐H, Random, 95% CI)

Totals not selected

3 Grade 1 ‐ 4 thrombocytopenia Show forest plot

1

Risk Ratio (M‐H, Random, 95% CI)

Totals not selected

4 Grade 3 ‐ 4 thrombocytopenia Show forest plot

1

Risk Ratio (M‐H, Random, 95% CI)

Totals not selected

Figuras y tablas -
Comparison 8. Gemcitabine plus mitomycin C versus capecitabine plus mitomycin C